The cost of at least 350 drugs in the U.S. are expected to rise in 2026, according to a new analysis, despite many of the ...
The White House announced Friday that nine additional pharmaceutical companies have agreed to follow President Trump’s “most ...
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...
To access our top 5 gated pieces of 2025, however, readers must first tell us a little bit about themselves.
Reimbursement policy in the US saw major upheaval in the second half of 2025. New mandates, stalled subsidy negotiations, and pricing pressures created major uncertainty for payers, providers, and ...
A hedge fund with an integral role in Yellow Corp.’s bankruptcy proceedings is pushing for shareholders to have a bigger say in the company’s upcoming liquidation. MFN Partners, which amassed a more ...
Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback